Immediate Destiny of Bifurcation Lesions Treated with Biomatrix Alpha Stents

Abstract

Abstract Background: About 15% of coronary artery interventions are performed on coronary artery bifurcation. Treatment of these lesions is one of the therapeutic challenges of coronary artery lesions. Correcting short-term and long-term unintended consequences of these lesions requires continuous attention and intervention. Ever since drug-eluting stents were developed,the expectancy of rescuing patients with cardiovascular events has increased. Methods: In this study, we selected 51 patients (out of 850) who had received ≥1 cobalt-chromium, biodegradable polymer, Biolimus A9-eluting stent (CoCr-BP-BES) Biomatrix Alpha stent. Immediately after stenting, thrombolysis in myocardial infarction (TIMI) flow score in the coronary artery and its bypass branch, plaque shift, and lateral dissection immediately after angioplasty, were evaluated. Results: The mean age for patients was 65 (±10.35) years, where 49.02% of them were male and 45.1% had diabetes. No, lateral dissection and death were reported in any of the patients. Also, the TIMI flow grade was 3 for the main branch in all patients. Plaque shifts were compared at different degrees of the TIMI flow coronary artery bypass graft. The statistical analysis showed a significant difference between groups. Controlling for gender, diabetes, systolic blood pressure and diastolic blood pressure with plaque shifts had no significant difference. Conclusions: We found that the immediate clinical outcomes for Biomatrix Alpha stents is admissible. In accordance with the current body of research on the latest-generation drug-eluting stent (DES), our results support the clinical benefit of the new biolimus-eluting (BES) stent technology that incorporating a biodegradable polymer, the BA-9 drug and a thin-strut CoCr stent platform.